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ABSTRACT	
	
Choosing	 an	 appropriate	 cell	 model(s)	 is	 the	 first	 decision	 to	 be	made	 before	
starting	a	new	project	or	programme	of	study.	Here,	we	address	the	rationale	that	
can	be	behind	this	decision	and	we	summarise	the	current	cell	models	that	are	
used	to	study	prostate	cancer.	Researchers	face	the	challenge	of	choosing	a	model	
that	recapitulates	the	complexity	and	heterogeneity	of	prostate	cancer.	The	use	of	
primary	prostate	epithelial	cells	cultured	from	patient	tissue	is	discussed,	and	the	
necessity	 for	 close	 clinical-academic	 collaboration	 in	 order	 to	 do	 this	 is	
highlighted.	Finally,	 a	novel	quantitative	phase	 imaging	 technique	 is	described,	
along	 with	 the	 potential	 for	 cell	 characterisation	 to	 not	 only	 include	 gene	
expression	and	protein	markers	but	also	morphological	features,	cell	behaviour	
and	kinetic	activity.		
	
	
	
	
	
	
	
	
	
	
	
	
INTRODUCTION	
The	foundation	of	all	studies,	whether	to	test	novel	therapeutic	agents	or	to	dissect	
molecular	 signaling	 pathways,	 is	 the	 cellular	model	 that	we	 choose	 (Figure	 1).	
Ultimately,	 every	 model	 has	 its	 advantages	 and	 limitations	 but	 all	 too	 often	
perhaps	 a	model	 is	 chosen	because	 of	 cost,	 convenience	 and	 accessibility	 first,	
with	 biological	 relevance	 coming	 lower	 down	 the	 list.	 Despite	 several	 drugs	
showing	promise	after	pre-clinical	testing,	many	clinical	trials	fail	(1,	2),	and	this	
is	after	testing	in	cell	models	as	well	as	in	xenografts	(3,	4).	Thus,	this	would	argue	
that	there	is	a	need	for	more	effective	pre-clinical	models	to	give	greater	chance	
of	success,	which	would	in	turn	mean	improved	patient	benefit	and	reduction	of	
wasted	 funds.	 Over	 the	 years	 several	 researchers	 have	 met	 the	 challenge	 to	
generate	 better	 and	 more	 relevant	 cellular	 models	 for	 prostate	 cancer	 (5-8).	
However,	with	prostate	cancer,	as	with	most	cancers,	a	single	model	cannot	be	
used	to	answer	all	questions.		
	
	
Current	Models	for	Prostate	Cancer	Research	
Prostate	cancer	research	has	relied	heavily	on	a	few	cell	 lines.	A	quick	Pubmed	
search	 shows	 >8000	 references	 using	 LNCaP	 cells,	 ~4000-5000	 for	 PC3	 and	
DU145	 cells	 and	 several	 others	 (22RV1,	 RWPE-1,	 VCaP)	 coming	 in	 at	 a	 few	
hundred	references	or	fewer.	There	is	a	perception	in	the	field	that	we	need	more	
cell	 lines	 for	prostate	cancer	but	 the	concern	 is	 that	new	cell	 lines	may	not	get	
disseminated	globally	 and	picked	up	by	 the	prostate	 community	 and	 therefore	
their	potential	is	not	realized;	this	may	already	be	the	case	for	existing	ones.	Cell	
lines	can	be	divided	into	four	main	groups,	cells	that	are	–	(i)	immortalized	by	viral	
oncogenes	(e.g.	HPV	and	SV40)	(5,	9-11),	(ii)	cultured	from	xenograft	tumours	(5,	
9,	10),	(iii)	derived	from	metastatic	lesions	(e.g.	ascites,	lymph	nodes,	bone)	(5,	9,	
10)	and	(iv)	immortalized	using	hTERT	(12-15).		The	latter	is	an	important	group	
because	 the	 cell	 phenotype	 is	 retained	 and	 there	 are	 no	 oncogenic	 changes	
associated	 with	 this	 method	 of	 immortalization	 (16).	 Also,	 this	 method	 has	
produced	pairs	of	cell	lines	(normal	and	cancer),	which	are	useful	for	comparison	
studies	(12,	14).	
	
The	 popularity	 of	 LNCaPs	 is	 obvious	 since	 for	 decades	 the	 design	 of	 new	
therapeutics	 has	 been	 focused	 on	 improving	 androgen	 deprivation	 drugs.	
However,	it	has	been	known	from	the	beginning	that	androgen	deprivation	was	
never	going	to	be	the	whole	answer	to	prostate	cancer	treatment	(17).	Castration-
resistant	prostate	cancer	and	metastatic	prostate	cancer	 remain	stubborn	 foes.	
More	 recently,	with	 the	 advent	 of	 ever	more	 sophisticated	 cell	 separation	 and	
genomic	techniques,	there	have	been	leaps	in	understanding	of	the	complexity	of	
prostate	cancer	and	its	evolutionary	progression	(18-24).		
	
Addressing	Prostate	Cancer	Heterogeneity	
The	 challenge	 with	 prostate	 cancer	 is	 to	 have	 cell	 line	 models	 that	 represent	
normal	 prostate,	 benign	 prostatic	 hyperplasia	 (BPH),	 Prostatic	 Intraepithelial	
Neoplasia	 (PIN),	 localized	 cancers	 of	 varying	 Gleason	 grades,	 aggressive	 and	
invasive	 cancers	 from	 within	 the	 prostate,	 metastatic	 cancers,	 hormone-
responsive	 cancers,	 castration-resistant	 cancers	 and	 neuroendocrine	 cancers.	
And	importantly	there	is	also	a	need	to	have	cell	lines	representing	different	races	
due	to	the	higher	incidence	of	prostate	cancer	in	African	American	men	(25).	In	
addition	 to	 the	 different	 disease	 states,	 severity	 and	 locations,	 there	 is	 further	
heterogeneity	to	take	into	account.	Prostate	cancer	is	a	multifocal	disease	so	there	
may	 be	more	 than	 one	 tumour	 in	 each	 patient	 (26)	 and	 there	 is	 inter-patient	
variability.	 Along	with	 this	 there	 is	 cellular	 heterogeneity	within	 each	 tumour,	
multiple	 gene	 mutations,	 gene	 fusions	 and	 epigenetic	 changes	 (27).	 Finding	 a	
cellular	 model(s)	 to	 address	 all	 of	 these	 parameters	 is	 challenging.	 However,	
understanding	and	acknowledging	heterogeneity	is	critical	in	terms	of	addressing	
diagnosis,	treatment,	resistance	and	recurrence	(28-30).	
	
Using	Primary	Prostate	Epithelial	Cells	as	a	Cell	Model		
Primary	cell	cultures	derived	from	human	prostate	tumours	have	the	potential	to	
be	 excellent	 cellular	 models	 to	 study	 the	 disease.	 They	 are	 clinically	 relevant,	
representative	of	current	disease	and	are	not	difficult	to	grow	(31-37).	However,	
one	limitation	is	that	they	can	usually	only	be	obtained	from	the	prostate	and	not	
metastatic	 sites.	 Using	 primary	 cells	 also	 opens	 up	 the	 possibility	 of	 testing	
multiple	patients	thereby	taking	into	account	patient	variation.	However,	this	also	
leads	to	the	challenge	of	assessing	and	interpreting	the	variation	in	response	that	
is	 observed.	How	do	we	decide	 how	many	patient	 samples	 is	 enough	within	 a	
single	study?	In	addition,	it	is	advisable	to	only	use	them	at	low	passages,	which	
limits	the	number	of	assays	that	can	be	done	on	each	sample.	
	
A	controversy	with	use	of	primary	prostate	patient	cells	is	the	potential	for	normal	
cells	to	overgrow	cancer	cells	(38,	39).	However,	several	studies	have	observed	
differences	between	normal	and	cancer	primary	prostate	epithelial	cells	such	as	
differential	 expression	 of	 matrix	 metalloproteinases,	 integrins,	 E-cadherin	 and	
behaviour	in	collagen	I	gels	(32,	40-42).	When	retrieving	our	samples,	we	have	a	
dedicated	 tissue	 procurement	 officer	 who	 samples	 the	 prostate	 post-radical	
prostatectomy	based	on	diagnostic	MRI	scans	and	trans-rectal	ultrasound	(TRUS)	
guided	biopsies,	taking	a	needle	core	from	a	palpable	tumour.		Our	own	studies	
have	shown	that	cancer	cultures	are	more	invasive	than	benign	cultures	(43),	are	
positive	for	the	TMPRSS2:ERG	fusion	at	low	passages	(44)	and	samples	from	high	
Gleason	grades	respond	differently	 to	drug	 than	benign	and	 low	Gleason	grade	
samples	(45).		
	
One	major	issue	within	the	field	is	the	lack	of	standardization	in	terms	of	culture	
media	between	laboratories.	There	are	differences	in	terms	of	the	supplements	
used,	some	being	chosen	for	their	ability	to	boost	cell	growth	(32,	33)	and	others	
to	maintain	a	stem/progenitor	population	within	 the	culture	 (31,	43,	46).	 	This	
makes	comparisons	between	studies	more	challenging.	
	
Undertaking	 a	 continual	 assessment	 and	 more	 complete	 characterization	 of	
primary	epithelial	cells	in	culture	is	needed.	The	advent	of	new	techniques	means	
that	 it	 is	 both	 possible	 and	 necessary	 to	 re-visit	 the	 characterization	 of	 these	
models.	 For	 this	 reason	 we	 are	 currently	 collecting	 both	 transit	 amplifying	
(progenitor)	 and	 committed	 basal	 cells	 (more	 differentiated)	 cultured	 from	 6	
samples	each	of	Normal,	BPH,	Gleason	6,	Gleason	7(3+4),	Gleason	7(4+3),	Gleason	
8(4+4)	and	Gleason	9	tissue	for	RNA	sequencing.	This	should	hopefully	identify	
new	markers	related	to	disease	status.	
	
Using	patient	 cells	 for	 a	 variety	of	 future	 studies	will	 ultimately	determine	 the	
utility	 of	 these	 cell	 cultures	 and	 provide	 support	 for	 strengthening	 clinical-
laboratory	relations	as	a	research	strategy.	However,	 if	more	 labs	are	to	access	
primary	patient	material	there	has	to	be	the	will,	the	funds	and	the	continuity	to	
make	a	network	of	relationships	work	(Figure	2).		
	
Using	Quantitative	 Phase	 Imaging	 (QPI)	 to	 Characterize	 a	 Cell	Model	 and	
Address	Heterogeneity		
Cell	characterization	usually	relates	to	gene	expression	patterns,	protein	markers	
and	cell	behavior	such	as	invasive	potential.	However,	in	order	to	also	take	into	
account	cell	heterogeneity	when	considering	the	effect	of	a	drug	or	radiation	on	
primary	cultures	there	are	two	ways	to	assess	their	response;	the	first	is	to	treat	
the	whole	population	of	cells	and	then	separate	out	different	cell	types,	and	the	
second	is	to	label	cells	with	a	fluorescent	marker	to	be	able	to	identify	cells	within	
the	 heterogeneous	 mixture.	 Both	 of	 these	 methods	 have	 their	 challenges;	 cell	
separation	is	a	laborious	procedure	and	it	could	be	argued	that	cells	change	their	
behaviour	when	 separate	 relative	 to	when	 they	 are	 a	mixture,	 and	 fluorescent	
labeling	by	whatever	means	always	has	the	potential	to	change	the	cell	behaviour.	
A	new	 technique	now	available	 is	 trying	 to	overcome	both	 these	challenges	by	
using	 quantitative	 phase	 imaging	 (QPI)	 on	 heterogeneous	 cultures	 to	 observe	
individual	cell	response	to	drugs	in	real-time.	The	LivecyteTM	is	a	microscope	that	
uses	the	principle	of	ptychography	to	generate	highly	contrasted	images	such	that	
several	parameters	can	be	measured	for	each	cell.	The	measurements	can	be	used	
to	 assess	 cell	 morphology	 (e.g.	 area,	 thickness	 sphericity),	 cell	 kinetics	 (e.g.	
velocity,	meandering	index)	and	population	dynamics.	For	more	detailed	studies	
using	this	 technology	see	these	references	(47-49).	The	potential	advantages	of	
this	technique	are	to	establish	cell	signatures	for	different	cell	types	and	to	identify	
rare	outlier	cells.	Our	previous	studies	using	this	technique	showed	that	prostate	
cell	lines	and	primary	prostate	epithelial	cells	differ	in	their	size,	speed	and	growth	
rates.	We	also	showed	that	the	transit	amplifying	cells	(TA)	and	committed	basal	
cells	(CB)	found	within	primary	cultures	have	different	cell	signatures,	with	the	
TA	cells	being	smaller,	thicker	and	faster	than	the	CB	cells	(27).		
	
Typical	drug	treatment	assays	 look	at	 the	average	population,	whether	there	 is	
reduction	in	cell	viability,	death	by	apoptosis	or	effect	on	colony	forming	ability.	
The	rare	cells	that	show	resistance	to	therapeutic	agent	are	likely	to	be	the	ones	
that	don’t	fit	in	with	the	average	and	are	therefore	masked	by	their	response.	By	
treating	every	cell	as	a	data-point	it	is	hoped	that	another	layer	can	be	peeled	away	
and	more	information	can	be	garnered	that	will	contribute	to	the	understanding	
of	 therapy	 resistance,	 tumour	 recurrence	 and	 identification	 of	 resistant	 cell	
features.	
	
We	 carried	 out	 a	 study	 using	 primary	 prostate	 epithelial	 cells	 treated	 with	
docetaxel,	a	standard	of	care	chemotherapy	treatment	 for	prostate	cancer.	Five	
concentrations	were	chosen	to	take	a	closer	look	at	cell	behavior	(Figure	3).	When	
looking	at	overall	metrics	it	became	clear	that	as	drug	concentration	increases,	cell	
motility	decreases,	measured	as	cell	velocity	and	meandering	index.	In	addition,	
the	sphericity	of	the	cells	increases	with	cells	entering	mitosis	and	not	being	able	
to	divide	due	to	the	effect	of	the	docetaxel	(50);	this	can	clearly	be	seen	in	the	video	
captured	by	the	LivecyteTM.	Interestingly,	when	looking	at	the	whole	population,	
particularly	at	something	like	sphericity,	a	bi-modal	or	tri-modal	response	can	be	
observed.	Thus,	it	is	necessary	to	closely	observe	the	videos	to	identify	unusual	
behaviour.	One	such	cell	is	represented	in	Figure	4.	In	comparison	to	the	healthy	
cell	that	divides,	and	a	cell	that	responds	to	drug	in	a	typical	way	(failing	to	divide,	
spreading	out	and	halting	movement),	we	also	show	the	outlier	cell	that	is	more	
erratic	 and	 sequentially	 rounds	 up,	 fails	 to	 divide	 and	 yet	 keeps	moving.	 Only	
further	analysis	of	outlier	cells	towards	their	ultimate	fate	will	determine	if	the	
power	 of	 this	 new	 technique	 can	 be	 harnessed	 to	 identify	 resistant	 cell	
populations.	
	
DISCUSSION		
Going	forward,	relationships	between	scientists,	clinicians	and	patients	are	critical	
for	 the	 progression	 of	 prostate	 cancer	 research.	 When	 addressing	 treatment	
response	and	tumour	recurrence,	there	are	several	levels	of	heterogeneity	to	take	
into	account,	which	can	only	be	done	through	use	of	patient	material.	Thus,	the	
feasibility	 of	 having	 primary	 cell	 cultures,	 which	 crucially	 represent	 modern	
disease,	 as	 a	 critical	 step	 in	 the	 lab	 to	 clinic	 pipeline,	 has	 to	 be	 explored.	 One	
successful	example	is	the	use	of	primary	cells	to	develop	an	oncolytic	adenovirus	
that	is	now	in	clinical	trials	(51,	52).		In	order	for	this	to	become	a	broad	reality,	
consistency,	reproducibility,	standardization	and	practicality	are	key.	The	method	
of	conditional	reprogramming	(CR)	(using	feeder	cells	and	ROCK	inhibitor)	has	
been	 used	 by	 researchers	 in	 other	 cancer	 research	 fields	 and	 also	 by	 some	
researchers	 in	 the	prostate	 field	 (53-55).	 This	 is	 another	method	 that	 requires	
further	 investigation	 and	 could	be	 explored	 alongside	 the	questioning	of	 other	
fundamentals	of	tissue	culture	such	as	oxygen	concentration;	several	studies	have	
shown	that	cells	can	grow	indefinitely	in	physiological	oxygen	concentrations	of	
2%	and	not	the	standard	20%	(56-58).		
	
The	desire	to	have	more	consistent	use	of	primary	cells	does	not	negate	the	need	
for	useful	 cell	 lines	but	 it	 does	highlight	 the	need	 to	 explore	 the	 cell	 lines	 that	
already	exist	because	there	may	already	be	the	correct	model	to	answer	critical	
research	 questions.	We	 also	 have	 to	 embrace	 new	 technology,	 to	 examine	 cell	
behaviour	 at	 another	 level	 of	 complexity.	 Combined	 with	 traditional	 markers	
these	 technologies	 could	 help	 to	 give	 a	 more	 complete	 idea	 of	 individual	 cell	
signatures	(Table	1).	
	
Currently	there	are	many	methods	that	can	translate	patient	prostate	tissue	to	2D	
cell	culture,	co-cultures	with	patient	stroma	and	3D	models	such	as	spheroids	and	
organoids	(Figure	5).	However,	the	range	of	media,	matrices	and	apparatus	that	
are	used	 are	 vast	 (40,	 59-67).	 There	 is	much	work	 to	 be	done	 if	 there	 is	 to	 be	
standardization	across	the	prostate	community	globally,	starting	with	the	will	to	
make	it	so.		
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Prostate Cancer Models: Every model has advantages and limitations.
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Collaborative network: In order to establish clinical collaborations, several parties
have to be invested and committed. There also has to be long-term continuity within
the laboratory to maintain the links and the knowledge. Once the clinical connections
are established, the tissue and cell resource attracts collaboration from other parties 
including academic departments and industry. The importance of the resource and the
nature of the work can also be disseminated through public engagement.
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Mean Instantaneous 
Velocity
Meandering Index Sphericity
Response of Primary Cells to Docetaxel: (A) A time-lapse movie was generated over 72 hours with
images captured at 6 minute intervals to observe the real-time response of primary prostate cells to
docetaxel. Untreated cells could be seen moving and dividing in a continuous motion (red arrow).
Dividing cell shown in white box insert. Treated cells predominantly responded by entering mitosis
(cells rounding up – blue outline arrow) and when mitosis failed, due to the effect of docetaxel, the
cells spread out and stopped moving (blue arrow). An outlier cell was observed that continuously
rounded up to try to divide but upon failure continued moving around in an erratic fashion (yellow
arrow). (B) Kinetic and morphological features can be extracted from the data. Each cell is measured
and patterns of response recorded. Bimodal responses are observed with some parameters that can
be related to the cell behaviour (turquoise circles). (Images were captured on a LivectyeTM and data
was analysed using the Cell Analysis Toolbox (CAT) software: www.phasefocus.com)
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Tracking Individual Cell Behaviour: (A) Individual cells were tracked over time following 
response to docetaxel treatment (100nM). Untreated (Healthy) cell has single direction of 
movement then divides and the daughter cell has meandering directionality. Typical cell 
response to docetaxel is to round up and enter mitosis then following incomplete mitosis the 
cell stops moving. The outlier (putative resistant cell) is much more erratic in its behaviour and 
is very motile. Following attempted divisions the cell maintains its highly motile behaviour. (B) 
Individual parameters also indicate the change in cell behaviour. Thickness clearly indicates 
the points at when the cell rounds up to enter mitosis.
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Figure 5
Patient Samples: Primary prostate epithelial cells can 
be cultured from patient tissue. These cells can be 
grown in 2D, in co-culture systems and in 3D culture. 
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